NCT07191834View on ClinicalTrials.gov

A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis

Not yet recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Rifampicin-resistant/Multidrug-resistant Pulmonary TuberculosisType 2 Diabetes Mellitus (T2DM)Pretomanid
All Listed Sponsors
lead

Wuhan Pulmonary Hospital

OTHER